Related Experiment Video
Updated: Jan 29, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N Gide1, Camelia Quek1, Alexander M Menzies2
1Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Abstract:
Cancer immunotherapies provide survival benefits in responding patients, but many patients fail to respond. Identifying the biology of treatment response and resistance are a priority to optimize drug selection and improve patient outcomes. We performed transcriptomic and immune profiling on 158 tumor biopsies from melanoma patients treated with anti-PD-1 monotherapy (n = 63) or combined anti-PD-1 and anti-CTLA-4 (n = 57). These data identified activated T cell signatures and T cell populations in responders to both treatments. Further mass cytometry analysis identified an EOMES+CD69+CD45RO+ effector memory T cell phenotype that was significantly more abundant in responders to combined immunotherapy compared with non-responders (n = 18). The gene expression profile of this population was associated with longer progression-free survival in patients treated with single agent and greater tumor shrinkage in both treatments.
Insights
Identifying specific T cell populations can predict patient response to cancer immunotherapy. An EOMES+ effector memory T cell phenotype is linked to better outcomes in melanoma patients treated with anti-PD-1 and anti-CTLA-4 therapies.
Area of Science:
- Immunology
- Oncology
- Translational Medicine
Background:
- Cancer immunotherapies like anti-PD-1 and anti-CTLA-4 offer survival benefits but lack efficacy in many melanoma patients.
- Understanding the biological mechanisms of treatment response and resistance is crucial for optimizing patient selection and improving outcomes.
Purpose of the Study:
- To identify key immune cell signatures associated with response to anti-PD-1 monotherapy and combined anti-PD-1/anti-CTLA-4 immunotherapy in melanoma.
- To characterize specific T cell phenotypes that correlate with treatment efficacy and predict patient outcomes.
Main Methods:
- Transcriptomic and immune profiling of 158 tumor biopsies from melanoma patients undergoing immunotherapy.
- Mass cytometry analysis to identify and quantify specific T cell populations, including effector memory phenotypes.
- Correlation analysis of immune cell profiles with clinical outcomes such as progression-free survival and tumor shrinkage.
Main Results:
- Activated T cell signatures and specific T cell populations were identified in responders to both single-agent and combination immunotherapy.
- A distinct EOMES+CD69+CD45RO+ effector memory T cell phenotype was significantly more abundant in responders to combination therapy.
- The gene expression profile of this effector memory T cell population correlated with longer progression-free survival in patients on single-agent therapy and greater tumor shrinkage in both treatment groups.
Conclusions:
- The EOMES+CD69+CD45RO+ effector memory T cell phenotype represents a potential biomarker for predicting response to combined immunotherapy in melanoma.
- Immune profiling can reveal distinct cellular mechanisms underlying response to different cancer immunotherapy strategies.
- These findings highlight the importance of characterizing specific immune cell subsets to guide treatment decisions and improve patient outcomes in melanoma.
More Related Videos
Related Concept Videos
Waterproofing and Anti-Bacterial Admixtures in Concrete
Waterproofing admixtures render concrete hydrophobic,...
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Radical Anti-Markovnikov Addition to Alkenes: Mechanism
The mechanism starts with chain initiation, which involves two steps. In the first chain initiation step, a weak peroxide bond is homolytically cleaved upon mild heating to form two alkoxy radicals. In the second initiation step, a hydrogen atom is abstracted by the alkoxy...
Oxidation of Alkenes: Anti Dihydroxylation with Peroxy Acids
Radical Anti-Markovnikov Addition to Alkenes: Overview
Radical Anti-Markovnikov Addition to Alkenes: Thermodynamics

